SCHEMBL22836745

SCHEMBL22836745

COC(=O)c1ccc2cn(CCCO)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 4/20 0.45
KDM4E B2RXH2 2/20 0.44
CYP4A11 Q02928 3/20 0.43
CYP4F2 P78329 2/20 0.43
TLR8 Q9NR97 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
IRAK4 Q9NWZ3 3/20 0.41
PDE4D Q08499 1/20 0.41
POLB P06746 1/20 0.41
JMJD6 Q6NYC1 1/20 0.40
ALOX15 P16050 1/20 0.40
HTT P42858 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
THRB P10828 1/20 0.39
EHMT2 Q96KQ7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3067040 0.90 IRAK4 (0.46) TLR7KDM4EALDH1A1TSHRHSD17B10
SCHEMBL12707008 0.88 TLR8 (0.48) TLR7KDM4ETLR8ALDH1A1TSHR
SCHEMBL24338407 0.87 KDM4E (0.46) TLR7KDM4EALDH1A1TSHRHSD17B10
SCHEMBL12707003 0.84 EHMT2 (0.57) TLR7KDM4ECYP4A11CYP4F2TLR8
SCHEMBL24337909 0.84 KDM4E (0.54) KDM4EALDH1A1TSHRHSD17B10POLB
SCHEMBL12707001 0.84 CNR2 (0.48) TLR7KDM4ETLR8ALDH1A1TSHR
SCHEMBL28274080 0.82 IRAK4 (0.48) TLR7KDM4ETLR8ALDH1A1TSHR
SCHEMBL13401292 0.82 THRB (0.47) KDM4EALDH1A1TSHRHSD17B10POLB
SCHEMBL12706996 0.82 ALDH1A1 (0.50) KDM4EALDH1A1TSHRHSD17B10CYP2C9
SCHEMBL3472264 0.81 THRB (0.60) KDM4EALDH1A1TSHRHSD17B10JMJD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-02-22 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-02 US disclosed
CN-114502158-A IRAK degradation agent and application thereof 凯麦拉医疗公司 2022-05-13 CN disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 EP disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TLR7 16/4885KDM4E 190/4885CYP4A11 2332/4885
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF IRAK4, IRAK2, IRAK3 TLR7 517/4885KDM4E 87/4885CYP4A11 3444/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TLR7 16/4885KDM4E 190/4885CYP4A11 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.